AlphAIAlphAI — Financial news for AI agents
aol.comAUG 233 min read$MCK

and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits.

McKesson (MCK) and Cencora (COR) are positioned to benefit from certain drug price inflation due to contractual provisions. McKesson reported $403.4B revenue and $39.11 EPS for fiscal 2026, with Q1 2027 revenue at $105.4B and EPS at $9.93. Cencora generated $321.3B revenue in fiscal 2025, with Q2 revenue at $78.4B and EPS at $4.75. Both companies have raised EPS forecasts.

Original reporting
aol.com
Published Aug 23, 2026, 10:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 23, 2026, 11:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
and Getting Worse. Here Are 2 Stocks That Turn Rising Prices Into Rising Profits. — source image
Source · aol.com
Decision brief

The 30-second read

$MCKBullishMed
01

Why it matters

Both firms delivered earnings beats and raised guidance, suggesting near‑term upside.

02

Market read

Earnings beats and guidance lifts for two large‑cap distributors provide a fresh bullish catalyst in a high‑inflation environment.

03

What to watch

Rising transportation and labor costs may offset inflation‑linked revenue gains.

Relevance 8/10Novelty 8/10Timing: post‑earnings release

Background

The article frames rising inflation as an investment theme and highlights two distributors that can profit from drug‑price increases.

Company-level read

Ticker impact

$MCKBullishHigh confidence
Context

McKesson reported FY2026 revenue of $403.4B (+12%) and raised FY2026 EPS guidance to $44.20‑$45.00 after Q1 2027 results.

Expected impact

Expect price to rally on the earnings beat and guidance lift.

Evidence & confidence

Revenue growth and higher EPS outlook beat expectations, reinforcing bullish sentiment.

$CORBullishHigh confidence
Context

Cencora posted Q2 revenue of $78.4B (+3.8%) and lifted FY2025 EPS outlook to $17.65‑$17.90.

Expected impact

Likely upward price movement as investors price in higher earnings.

Evidence & confidence

Both top‑line growth and higher guidance support a bullish outlook.

Market effects

Sector

Pharma distribution sector benefits from inflation‑linked contracts, potentially outpacing peers.

Regional

U.S. healthcare distribution stocks may see relative strength amid broader inflation concerns.

Global

Large-cap distributors could influence global drug‑price dynamics and related ETFs.

Counterpoint

What could challenge this read

If drug‑price inflation eases, both companies could see margin compression despite growth.

Key entities

  • company
    McKesson

    Pharmaceutical distributor with inflation‑linked contracts.

  • company
    Cencora

    Pharmaceutical distributor with similar price‑appreciation provisions.

Read at source← All news

Related articles

SEP 15
$MCKMed

Does Raised EPS Guidance Change The Bull Case For McKesson Stock (MCK)?

McKesson (MCK) raised its full-year EPS guidance to 13-15% (15-17% excluding prior-year items) and plans to rebrand its Medical-Surgical unit as Wellverse, targeting an IPO in 2H 2027. The company also aims to acquire Precision Medicine Group to expand oncology and biopharma services. Management highlights core operations are tracking ahead, but structural pressures on drug pricing and high leverage remain risks. McKesson projects $502.2B revenue and $6.3B earnings by 2029, implying 6.9% yearly

simplywall.st3 min
SEP 14
$MCKHigh

McKesson Raises Outlook, Eyes Oncology Growth With Precision Medicine Deal

McKesson (MCK) raised its outlook, citing growth in its Oncology & Multispecialty segment, which saw 33% revenue growth and 41% adjusted operating profit growth in Q1. The company also announced a deal for Precision Medicine Group, expected to be strategically and financially accretive. McKesson's RxTS segment grew 9% in revenue and 13% in adjusted operating profit, with GLP-1-related business accounting for 11% of its revenue. The company plans to invest more in growth, automation, and technolo

yahoo.com2 min
SEP 10
$CORHighAI 8/10

Is Cencora Stock Underperforming the Dow?

Cencora (COR), a $61.6B pharmaceutical distributor, is down 14% from its 52-week high but up 18.5% over 3 months, outperforming the Dow. Its Q3 revenue missed estimates, but adjusted EPS beat forecasts. Analysts rate it a 'Strong Buy' with a $366.50 target, implying 12.9% upside. Peer Cardinal Health (CAH) gained 60% over the past year.

yahoo.com2 min
SEP 8
$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

yahoo.com3 min
SEP 8
$MCKMed

McKesson Eyes $2.25B Precision Medicine Deal as Oncology Growth Accelerates

McKesson (MCK) plans a $2.25B precision medicine acquisition, expecting strategic alignment and value creation. Q1 revenue grew 5% in North American Pharmaceutical Distribution and 33% in Oncology. The company aims to return $5B to shareholders this year, including $2.5B in share repurchases and a 15% dividend increase. McKesson also expects to separate its Medical-Surgical business, rebranded as Wellverse, by late 2024.

yahoo.com6 min